(Q37385960)

20 August 2017

1 reference

title

Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations (English)

1 reference

20 August 2017

main subject

dasatinib monohydrate

1 reference

1 reference

5

Jorge E Cortes

1 reference

20 August 2017

Hanna Jean Khoury

1

1 reference

20 August 2017

François Guilhot

series ordinal

2

1 reference

20 August 2017

Timothy P Hughes

series ordinal

3

1 reference

20 August 2017

Dong-Wook Kim

series ordinal

4

1 reference

20 August 2017

language of work or name

English

0 references

publication date

1 April 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

115

1 reference

20 August 2017

issue

7

1 reference

20 August 2017

page(s)

1381-1394

1 reference

Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges

20 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24155

21 January 2018

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24155

7 January 2021

Natural history and staging of chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24155

7 January 2021

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24155

7 January 2021

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24155

7 January 2021

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24155

7 January 2021

Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24155

7 January 2021

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24155

7 January 2021

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24155

7 January 2021

Sprycel for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to or intolerant of imatinib mesylate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24155

7 January 2021

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24155

7 January 2021

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24155

7 January 2021

Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24155

7 January 2021

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24155

7 January 2021

Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24155

7 January 2021

Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24155

7 January 2021

Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24155

7 January 2021

Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24155

7 January 2021

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24155

7 January 2021

Pleural Effusion in Patients With Chronic Myelogenous Leukemia Treated With Dasatinib After Imatinib Failure

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24155

7 January 2021

Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24155

7 January 2021

Biology of platelet-derived growth factor and its involvement in disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24155

7 January 2021

Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24155

7 January 2021

A renaissance for SRC

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24155

7 January 2021

Regulation of angiogenesis and vascular permeability by Src family kinases: opportunities for therapeutic treatment of solid tumors.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24155

7 January 2021

Lung Abnormalities after Dasatinib Treatment for Chronic Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24155

7 January 2021

Practical management of patients with chronic myeloid leukemia receiving imatinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24155

7 January 2021

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24155

7 January 2021

Identifiers

DOI

10.1002/CNCR.24155

1 reference

release_4zaqpwp7jnhlzojoj7yhtrnyu4

20 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4zaqpwp7jnhlzojoj7yhtrnyu4

24 November 2022

mapped directly with Wikidata item

1 reference